AI-guided exercise and recovery program for people with coronary heart disease

Artificial Intelligence-enhanced Stratified Management Platform Guiding Home-based Exercise Rehabilitation for Coronary Heart Disease Patients: a Randomized Control Trial

This project will see if a smartphone AI program combined with a wristband helps adults with coronary heart disease do home exercise after leaving the hospital and improves their fitness and heart-risk measures.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 200 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: China National Center for Cardiovascular Diseases (other gov)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT07259278 on ClinicalTrials.gov

What this trial studies

Adults with coronary heart disease who are classified as low exercise risk will be assigned to either an AI-enabled stratified management platform used with a sports wristband or to routine post-discharge care and followed for three months. The AI platform provides personalized exercise prescriptions, remote monitoring via the wristband, motivational support, and tailored risk-factor management through a smartphone app. The primary outcome is change in peak oxygen consumption (VO2peak) at 3 months, with secondary outcomes including daily physical activity, exercise adherence and motivation, control of modifiable cardiovascular risk factors, and safety of home-based exercise. Baseline and follow-up visits occur at Fuwai Hospital with ongoing remote data collection through the app and wearable.

Who should consider this trial

Good fit: Adults over 18 with coronary heart disease who are judged low-risk for exercise by the GRACE score, can use a smartphone (or have a caregiver who can), and are willing to provide informed consent are ideal candidates.

Not a fit: Patients with recent myocardial infarction, planned revascularization, significant left main or major vessel stenosis, severe cognitive or exercise impairment, advanced malignancy, multi-organ failure, or life expectancy under three months are unlikely to benefit or to be eligible.

Why it matters

Potential benefit: If successful, the platform could help patients increase exercise capacity, improve adherence to home rehabilitation, and better control cardiovascular risk factors.

How similar studies have performed: Previous telerehabilitation and digital cardiac rehabilitation programs have improved adherence and exercise capacity, but AI-driven stratified management platforms are relatively novel and less extensively tested.

Eligibility criteria

Inclusion Criteria:

* CHD patients aged over 18 years;
* Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score.
* Ability of the patient or close relatives to use smartphones and applications;
* Willingness to participate and sign the informed consent form.

Exclusion Criteria:

* Residual stenosis of \>50% in the left main coronary artery, or \>70% stenosis in other major epicardial vessels;
* Planned coronary revascularization within the next 3 months;
* Acute myocardial infarction within the past 1 month;
* Severe cognitive impairment;
* Severely impaired exercise capacity.
* Advanced-stage malignancy;
* Life expectancy less than 3 months;
* Severe multi-organ failure;
* Other conditions deemed unsuitable for home-based exercise rehabilitation following assessment by a specialist rehabilitation physician.
* Refusal to provide written informed consent.

Where this trial is running

Beijing, Beijing Municipality

• Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases — Beijing, Beijing Municipality, China (RECRUITING)

Study contacts

• Study coordinator: Prof. Gao, MD, PhD

Conditions: Secondary Prevention of Coronary Heart Disease